<p>AlloVir 的股东在周三举行的特别会议上批准了公司与 Kalaris Therapeutics 的合并提案，双方当天均表示。</p>
<p>合并预计将在 “尽快” 完成，合并后的公司将更名为 Kalaris Therapeutics，纳斯达克的交易代码将更新为 “KLRS”。</p>

ALVR

KLRS

<p>AlloVir 的股东在周三举行的特别会议上批准了公司与 Kalaris Therapeutics 的合并提案，双方在同一天表示。合并预计将在 “尽快” 完成，合并后的公司将更名为 Kalaris Therapeutics，更新后的纳斯达克交易代码为 “KLRS”</p>

<p>AlloVir shareholders have approved the company's proposed merger with Kalaris Therapeutics at a special meeting held Wednesday, the companies said the same day.</p>
<div class="lb-trans"><p>AlloVir 的股东在周三举行的特别会议上批准了公司与 Kalaris Therapeutics 的合并提案，双方当天均表示。</p>
</div><p>The merger is expected to close &#34;as soon as practicable&#34; and the combined company will be renamed as Kalaris Therapeutics, with &#34;KLRS&#34; as its updated trading symbol on Nasdaq.</p>
<div class="lb-trans"><p>合并预计将在 “尽快” 完成，合并后的公司将更名为 Kalaris Therapeutics，纳斯达克的交易代码将更新为 “KLRS”。</p>
</div>

AlloVir 股东批准与 Kalaris Therapeutics 的合并